ArticleNPJ vaccines2026
Self-destructing attenuated adjuvant Salmonella serves as a safe and potent live vaccine adjuvant.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Next-generation vaccine adjuvants, including live bacterial platforms such as Salmonella, must enhance antigen-specific immune responses while maintaining an optimal safety profile, particularly for mucosal delivery. We report a rationally engineered live attenuated Salmonella adjuvant platform, self-destructing attenuated adjuvant Salmonella (SDAAS), designed for effective innate immune stimulation with built-in biosafety. Three candidate strains, χ12612, χ12621, and χ12626, were developed incorporating programmed auxotrophy for self-limiting growth, lipid A and lipopolysaccharide carbohydrate modifications to reduce endotoxin activity, and engineered flagellin. The SDAAS strains exhibited self-limiting growth, high LD₅₀ values across injection routes, and complete safety following parenteral and mucosal administration. In vitro assays showed minimal cytotoxicity, while functional analyses demonstrated robust TLR4 activation with reduced endotoxin activity from lipid A engineering and strong TLR5 signaling mediated by modified flagellin. Using ovalbumin as a model antigen, transcriptomic analysis revealed broad activation of proinflammatory, pattern recognition receptor, and antigen presentation pathways, most prominently in strain χ12621. These innate signatures correlated with elevated IL-6 and TNF-α, low IL-10, and strong antigen-specific IgG responses comparable to or exceeding those induced by alum and other commercial adjuvants. Collectively, these findings establish SDAAS strains as safe, tunable, and broadly applicable adjuvant platforms for mucosal and systemic vaccine delivery.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.